Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.41
PRXL's Cash-to-Debt is ranked lower than
75% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.44 vs. PRXL: 0.41 )
Ranked among companies with meaningful Cash-to-Debt only.
PRXL' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.17  Med: 4.08 Max: No Debt
Current: 0.41
Equity-to-Asset 0.26
PRXL's Equity-to-Asset is ranked lower than
88% of the 208 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. PRXL: 0.26 )
Ranked among companies with meaningful Equity-to-Asset only.
PRXL' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.24  Med: 0.45 Max: 0.72
Current: 0.26
0.24
0.72
Interest Coverage 18.68
PRXL's Interest Coverage is ranked lower than
60% of the 152 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 59.16 vs. PRXL: 18.68 )
Ranked among companies with meaningful Interest Coverage only.
PRXL' s Interest Coverage Range Over the Past 10 Years
Min: 3.16  Med: 6.29 Max: 28.51
Current: 18.68
3.16
28.51
Piotroski F-Score: 5
Altman Z-Score: 3.65
Beneish M-Score: -2.96
WACC vs ROIC
5.70%
14.75%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 8.57
PRXL's Operating Margin % is ranked higher than
62% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.05 vs. PRXL: 8.57 )
Ranked among companies with meaningful Operating Margin % only.
PRXL' s Operating Margin % Range Over the Past 10 Years
Min: 5.49  Med: 6.55 Max: 9.23
Current: 8.57
5.49
9.23
Net Margin % 4.96
PRXL's Net Margin % is ranked higher than
63% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.21 vs. PRXL: 4.96 )
Ranked among companies with meaningful Net Margin % only.
PRXL' s Net Margin % Range Over the Past 10 Years
Min: 3.11  Med: 4.44 Max: 6.38
Current: 4.96
3.11
6.38
ROE % 19.84
PRXL's ROE % is ranked higher than
88% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.23 vs. PRXL: 19.84 )
Ranked among companies with meaningful ROE % only.
PRXL' s ROE % Range Over the Past 10 Years
Min: 9.33  Med: 14.95 Max: 23.85
Current: 19.84
9.33
23.85
ROA % 5.63
PRXL's ROA % is ranked higher than
72% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.45 vs. PRXL: 5.63 )
Ranked among companies with meaningful ROA % only.
PRXL' s ROA % Range Over the Past 10 Years
Min: 3.4  Med: 5.96 Max: 7.99
Current: 5.63
3.4
7.99
ROC (Joel Greenblatt) % 45.33
PRXL's ROC (Joel Greenblatt) % is ranked higher than
78% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.76 vs. PRXL: 45.33 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PRXL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 21.41  Med: 44.37 Max: 58.04
Current: 45.33
21.41
58.04
3-Year Revenue Growth Rate 10.10
PRXL's 3-Year Revenue Growth Rate is ranked higher than
64% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.50 vs. PRXL: 10.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PRXL' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 5.3  Med: 15.3 Max: 39.5
Current: 10.1
5.3
39.5
3-Year EBITDA Growth Rate 17.40
PRXL's 3-Year EBITDA Growth Rate is ranked higher than
73% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. PRXL: 17.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PRXL' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -11.3  Med: 16.55 Max: 56.4
Current: 17.4
-11.3
56.4
3-Year EPS without NRI Growth Rate 21.10
PRXL's 3-Year EPS without NRI Growth Rate is ranked higher than
72% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.80 vs. PRXL: 21.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PRXL' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -32.8  Med: 18.9 Max: 40.6
Current: 21.1
-32.8
40.6
GuruFocus has detected 6 Warning Signs with Parexel International Corp $PRXL.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PRXL's 30-Y Financials

Financials (Next Earnings Date: 2017-08-03 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

PRXL Guru Trades in Q3 2016

Joel Greenblatt 64,743 sh (New)
Steven Cohen 103,800 sh (+413.86%)
Vanguard Health Care Fund 1,168,440 sh (unchged)
Chuck Royce 293,600 sh (unchged)
Paul Tudor Jones Sold Out
Ken Fisher 2,312,019 sh (-1.07%)
» More
Q4 2016

PRXL Guru Trades in Q4 2016

Paul Tudor Jones 82,309 sh (New)
Jana Partners 745,665 sh (New)
Joel Greenblatt 120,706 sh (+86.44%)
Steven Cohen Sold Out
Ken Fisher 2,244,444 sh (-2.92%)
Vanguard Health Care Fund 1,108,785 sh (-5.11%)
Chuck Royce 239,400 sh (-18.46%)
» More
Q1 2017

PRXL Guru Trades in Q1 2017

Vanguard Health Care Fund 1,108,785 sh (unchged)
Jana Partners Sold Out
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
Ken Fisher 2,160,308 sh (-3.75%)
Chuck Royce 148,000 sh (-38.18%)
» More
Q2 2017

PRXL Guru Trades in Q2 2017

Ken Fisher 2,114,547 sh (-2.12%)
» More
» Details

Insider Trades

Latest Guru Trades with PRXL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 541711    SIC: 8731
Compare:NYSE:ALR, NAS:VWR, NAS:EXAS, NAS:BRKR, NAS:PRAH, NYSE:CRL, NAS:INCR, NAS:DXCM, NAS:NEOG, NYSE:BIO.B, NAS:MYGN, NAS:AXDX, NAS:FMI, NYSE:PKI, NAS:VREX, NAS:ABAX, NAS:MEDP, NAS:GHDX, NAS:BEAT, NAS:QDEL » details
Traded in other countries:PAX.Germany,
Headquarter Location:USA
Parexel International Corp is a biopharmaceutical services company. It offers clinical research, clinical logistics, medical communications, and technology products and services to the pharmaceutical, biotechnology, and medical device industries.

Parexel is a global contract research organization that provides outsourced research and development services to pharmaceutical and biotechnology companies. Although the firm's clinical research services segment brings in the lion's share of revenue, Parexel also offers technical expertise and advice through its consulting and medical communications services segment, as well as information technology solutions through its Perceptive Informatics segment.

Ratios

vs
industry
vs
history
PE Ratio 38.72
PRXL's PE Ratio is ranked lower than
51% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.78 vs. PRXL: 38.72 )
Ranked among companies with meaningful PE Ratio only.
PRXL' s PE Ratio Range Over the Past 10 Years
Min: 6.5  Med: 26.12 Max: 42.45
Current: 38.72
6.5
42.45
Forward PE Ratio 22.12
PRXL's Forward PE Ratio is ranked higher than
69% of the 35 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.92 vs. PRXL: 22.12 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 38.72
PRXL's PE Ratio without NRI is ranked higher than
50% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 38.46 vs. PRXL: 38.72 )
Ranked among companies with meaningful PE Ratio without NRI only.
PRXL' s PE Ratio without NRI Range Over the Past 10 Years
Min: 6.5  Med: 26.06 Max: 42.45
Current: 38.72
6.5
42.45
Price-to-Owner-Earnings 16.73
PRXL's Price-to-Owner-Earnings is ranked higher than
81% of the 68 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.54 vs. PRXL: 16.73 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
PRXL' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 10.05  Med: 21.64 Max: 256.94
Current: 16.73
10.05
256.94
PB Ratio 7.81
PRXL's PB Ratio is ranked lower than
81% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.89 vs. PRXL: 7.81 )
Ranked among companies with meaningful PB Ratio only.
PRXL' s PB Ratio Range Over the Past 10 Years
Min: 0.98  Med: 3.58 Max: 8
Current: 7.81
0.98
8
PS Ratio 1.91
PRXL's PS Ratio is ranked higher than
75% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.65 vs. PRXL: 1.91 )
Ranked among companies with meaningful PS Ratio only.
PRXL' s PS Ratio Range Over the Past 10 Years
Min: 0.33  Med: 1.22 Max: 1.91
Current: 1.91
0.33
1.91
Price-to-Free-Cash-Flow 14.46
PRXL's Price-to-Free-Cash-Flow is ranked higher than
81% of the 78 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.07 vs. PRXL: 14.46 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
PRXL' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.42  Med: 18.85 Max: 127.89
Current: 14.46
9.42
127.89
Price-to-Operating-Cash-Flow 11.69
PRXL's Price-to-Operating-Cash-Flow is ranked higher than
82% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.14 vs. PRXL: 11.69 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
PRXL' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.13  Med: 13.09 Max: 132.14
Current: 11.69
5.13
132.14
EV-to-EBIT 23.54
PRXL's EV-to-EBIT is ranked higher than
60% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. PRXL: 23.54 )
Ranked among companies with meaningful EV-to-EBIT only.
PRXL' s EV-to-EBIT Range Over the Past 10 Years
Min: 5.9  Med: 17.2 Max: 25.2
Current: 23.54
5.9
25.2
EV-to-EBITDA 15.69
PRXL's EV-to-EBITDA is ranked higher than
64% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.58 vs. PRXL: 15.69 )
Ranked among companies with meaningful EV-to-EBITDA only.
PRXL' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.3  Med: 11.1 Max: 16.1
Current: 15.69
4.3
16.1
PEG Ratio 1.78
PRXL's PEG Ratio is ranked higher than
75% of the 48 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.20 vs. PRXL: 1.78 )
Ranked among companies with meaningful PEG Ratio only.
PRXL' s PEG Ratio Range Over the Past 10 Years
Min: 0.24  Med: 1.4 Max: 12.81
Current: 1.78
0.24
12.81
Shiller PE Ratio 53.55
PRXL's Shiller PE Ratio is ranked lower than
65% of the 31 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 47.44 vs. PRXL: 53.55 )
Ranked among companies with meaningful Shiller PE Ratio only.
PRXL' s Shiller PE Ratio Range Over the Past 10 Years
Min: 23.29  Med: 53.31 Max: 124
Current: 53.55
23.29
124
Current Ratio 1.48
PRXL's Current Ratio is ranked lower than
76% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.73 vs. PRXL: 1.48 )
Ranked among companies with meaningful Current Ratio only.
PRXL' s Current Ratio Range Over the Past 10 Years
Min: 1.21  Med: 1.63 Max: 3.36
Current: 1.48
1.21
3.36
Quick Ratio 1.48
PRXL's Quick Ratio is ranked lower than
67% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. PRXL: 1.48 )
Ranked among companies with meaningful Quick Ratio only.
PRXL' s Quick Ratio Range Over the Past 10 Years
Min: 1.21  Med: 1.63 Max: 3.36
Current: 1.48
1.21
3.36
Days Sales Outstanding 86.46
PRXL's Days Sales Outstanding is ranked lower than
70% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.84 vs. PRXL: 86.46 )
Ranked among companies with meaningful Days Sales Outstanding only.
PRXL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 72.14  Med: 129.1 Max: 149.34
Current: 86.46
72.14
149.34
Days Payable 13.20
PRXL's Days Payable is ranked lower than
91% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 57.91 vs. PRXL: 13.20 )
Ranked among companies with meaningful Days Payable only.
PRXL' s Days Payable Range Over the Past 10 Years
Min: 7.12  Med: 13.49 Max: 17.88
Current: 13.2
7.12
17.88

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 2.10
PRXL's 3-Year Average Share Buyback Ratio is ranked higher than
96% of the 146 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.50 vs. PRXL: 2.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PRXL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -21.2  Med: -1.4 Max: 2.8
Current: 2.1
-21.2
2.8

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.61
PRXL's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
70% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.25 vs. PRXL: 1.61 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
PRXL' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.16  Med: 2.21 Max: 7.33
Current: 1.61
1.16
7.33
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.45
PRXL's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
72% of the 18 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.07 vs. PRXL: 1.45 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.57
PRXL's Price-to-Median-PS-Value is ranked lower than
80% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.04 vs. PRXL: 1.57 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PRXL' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.32  Med: 0.87 Max: 3.15
Current: 1.57
0.32
3.15
Price-to-Peter-Lynch-Fair-Value 1.94
PRXL's Price-to-Peter-Lynch-Fair-Value is ranked higher than
70% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.52 vs. PRXL: 1.94 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
PRXL' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.39  Med: 1.71 Max: 16.68
Current: 1.94
0.39
16.68
Earnings Yield (Greenblatt) % 4.25
PRXL's Earnings Yield (Greenblatt) % is ranked higher than
80% of the 230 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.04 vs. PRXL: 4.25 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PRXL' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 4  Med: 5.8 Max: 16.9
Current: 4.25
4
16.9
Forward Rate of Return (Yacktman) % 23.23
PRXL's Forward Rate of Return (Yacktman) % is ranked higher than
86% of the 65 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.57 vs. PRXL: 23.23 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
PRXL' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 4  Med: 21.1 Max: 33.7
Current: 23.23
4
33.7

More Statistics

Revenue (TTM) (Mil) $2,419.40
EPS (TTM) $ 2.26
Beta0.64
Short Percentage of Float7.72%
52-Week Range $51.16 - 87.86
Shares Outstanding (Mil)51.05

Analyst Estimate

Jun17 Jun18 Jun19
Revenue (Mil $) 2,097 2,210 2,358
EPS ($) 3.23 3.96 4.81
EPS without NRI ($) 3.23 3.96 4.81
EPS Growth Rate
(Future 3Y To 5Y Estimate)
9.06%
Dividends per Share ($)
» More Articles for PRXL

Headlines

Articles On GuruFocus.com
Harwood Feffer LLP Announces Investigation of PAREXEL International Corporation Jun 20 2017 
PAREXEL INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investiga Jun 20 2017 
Parexcel: Great Growth but a Tough Business Aug 17 2011 
PAREXEL International Corp. (PRXL) Senior VP & CFO James F Jr Winschel sells 12,920 Shares Mar 11 2011 
PAREXEL International Corp. (PRXL) Senior VP & CFO James F Jr Winschel sells 1,500 Shares Mar 11 2011 
PAREXEL International Corp. Reports Operating Results (10-Q) Feb 09 2011 
PAREXEL International Corp. Reports Operating Results (10-Q) Nov 09 2010 
PAREXEL International Corp. Reports Operating Results (10-K/A) Sep 09 2010 
PAREXEL International Corp. Reports Operating Results (10-K) Aug 27 2010 
PAREXEL International Corp. Reports Operating Results (10-Q) May 07 2010 

More From Other Websites
PAREXEL (PRXL) Gets CEO Cancer Gold Standard Accreditation Jul 12 2017
PAREXEL Receives CEO Cancer Gold Standard Re-Accreditation Jul 11 2017
Lifshitz&Miller LLP Announces Investigation of ARI Network Services, Inc., DuPont Fabros Technology,... Jul 03 2017
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether... Jun 27 2017
PAREXEL Named to the Forbes America’s Best Employers List for Second Consecutive Year Jun 26 2017
The Law Offices of Vincent Wong Notifies Investors of an Investigation of PAREXEL International... Jun 22 2017
SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of PAREXEL International... Jun 22 2017
Featured Company News - Pamplona to Acquire PAREXEL; Another Contract Researcher Goes Private Jun 22 2017
SHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Proposed Sale of PAREXEL... Jun 21 2017
PAREXEL INTERNATIONAL CORPORATION SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe Investigates... Jun 21 2017
INVESTOR ALERT: Levi & Korsinsky, LLP Remind Investors of an Investigation Concerning Whether the... Jun 21 2017
Company News for June 21, 2017 Jun 21 2017
PAREXEL Announces Acquisition by Pamplona Capital for $5B Jun 21 2017
[$$] Drug-Research Shake Up Continues as Pamplona Reaches Deal to Buy Parexel Jun 21 2017
Harwood Feffer LLP Announces Investigation of PAREXEL International Corporation Jun 20 2017
Parexel, Lennar rise; Teladoc, Chipotle Mexican Grill fall Jun 20 2017
PAREXEL INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC... Jun 20 2017
​Waltham-based Parexel will go private in $5B deal Jun 20 2017
PAREXEL INTERNATIONAL CORPORATION SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation... Jun 20 2017
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of... Jun 20 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}